Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Gains from Sales and Divestitures (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $5628.0 as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 5209.43% to $5628.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $5628.0, a 5209.43% increase, with the full-year FY2024 number at $6788.0, down 88.5% from a year prior.
  • Gains from Sales and Divestitures was $5628.0 for Q3 2025 at bioAffinity Technologies, down from $121408.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $121408.0 in Q2 2025 to a low of $106.0 in Q3 2024.
  • A 4-year average of $36988.0 and a median of $10736.0 in 2024 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 88.5% in 2024, then skyrocketed 5209.43% in 2025.
  • bioAffinity Technologies' Gains from Sales and Divestitures stood at $29728.0 in 2022, then skyrocketed by 98.64% to $59051.0 in 2023, then tumbled by 88.5% to $6788.0 in 2024, then decreased by 17.09% to $5628.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Gains from Sales and Divestitures are $5628.0 (Q3 2025), $121408.0 (Q2 2025), and $92601.0 (Q1 2025).